linjc16/ctgov huggingface dataset:
Effect of Hypnosis on Motor Cortex Excitability

Study Overview
=================
Brief Summary
-----------------
This study is intended to investigate neurophysiological mechanisms of hypnosis using transcranial magnetic stimulation (TMS) and assessment of motor cortex excitability in healthy volunteers under hypnosis.

Official Title
-----------------
Effect of Hypnosis on Motor Cortex Excitability

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Hypnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Healthy volunteers aged 20 to 45 years. Hypnotisability above 14 as measured by the Tellegan absorption scale. Exclusion Criteria: Psychiatric diagnosis in axis I or axis II; Documented history of head injury or seizure disorder; Evidence of a disorder which could affect peripheral and central conduction such as multiple sclerosis, motor neuron disease, carpal tunnel syndrome, cervical spondylosis, diabetic neuropathy. Any other contraindication to TMS as specified in the safety guidelines for rTMS (Wassermann, 1998) such as cardiac pacemakers or metallic deep brain electrodes. Chronic pharmacological treatment.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Hypnosis|Hypnosis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cortical Excitability |  | Before and after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypnosis, TMS, Cortical excitability
Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes

Study Overview
=================
Brief Summary
-----------------
Surgical outcome of vitrectomy for myopic traction maculopathy in highly myopic eyes was evaluated in each stage. Efficacy of internal limiting membrane was also evaluated whether it may improve visual outcome.

Detailed Description
-----------------
Surgical outcome of vitrectomy for myopic traction maculopathy in highly myopic eyes was evaluated in each stage of macular retinischisis, foveal detachment, or macular hole. Efficacy of internal limiting membrane was also evaluated whether it may improve visual outcome.

Official Title
-----------------
Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes

Conditions
-----------------
Maculopathy, High Myopia, Surgery

Intervention / Treatment
-----------------
* Procedure: vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eyes with myopic traction maculopathy in highly myopic eyes with refractive errors ≤ -8.0 diopters and axial length ≥ 26.0 mm who underwent vitrectomy Exclusion Criteria: Eyes with follow-up less than a year

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Myopic traction maculopathy<br>The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed. | Procedure: vitrectomy<br>* Surgery<br>* Other names: Myopic traction maculopathy in highly myopic eyes;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Preoperative and postoperative visual acuity | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optical coherence tomography | Anatomical retinal images by optical cohernce tomography | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myopic traction maculopathy, vitrectomy, internal limiting membrane, Retrospective, case control study
Interactions Between Cranberry Juice and Antibiotics Used to Treat Urinary Tract Infections

Study Overview
=================
Brief Summary
-----------------
The purpose of study is to determine whether cranberry juice interacts with antibiotics used to treat urinary tract infections (UTIs).

Detailed Description
-----------------
Although evidence of its effectiveness is limited, cranberry juice is widely used to prevent urinary tract infections (UTIs). However, recent studies have shown that cranberry juice may affect the way the body absorbs and metabolizes antibiotics used to treat UTIs. This study will determine whether concurrent cranberry juice administration lowers the urinary concentrations of two commonly used antibiotics, amoxicillin and cefaclor. This study will involve children being treated for UTIs and adults without UTIs. All of the children will continue their prescribed amoxicillin/cefaclor treatment. After 7 to 10 days of antibiotic treatment, the children will be assigned to receive either cranberry juice for 2 days or no additional treatment. Urine samples will be collected from all child participants before and after the administration of cranberry juice to examine the excretion of the antibiotics. Adult participants will receive two different doses of amoxicillin, with or without cranberry juice. Blood and urine samples will be collected to evaluate the effect of cranberry juice on the absorption and elimination of amoxicillin.

Official Title
-----------------
Cranberry: Interactions With Anti-Infectious Agents

Conditions
-----------------
Urinary Tract Infections

Intervention / Treatment
-----------------
* Drug: Cranberry juice
* Drug: Amoxicillin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Children: Urinary tract infection (UTI) treated with cefaclor or amoxicillin Inclusion Criteria for Adults: No UTI Exclusion Criteria: Allergies to antibiotics Use of medications other than oral contraceptives Pregnancy or breast-feeding Smoker

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cranberry juice|nan|
|Drug: Amoxicillin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug Elmination |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug absorption |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccinium macrocarpon
Treatment of Initial Clostridium Difficile Infection

Study Overview
=================
Brief Summary
-----------------
Investigators designed an open, two-arm study to compare oral vancomycin with a fecal microbiota transplant (FMT) from a fecal donor-unrelated donor mix (FURM) as treatments for the first Clostridium difficile infection (CDI) episode among hospitalized patients.

Detailed Description
-----------------
Investigators designed an open, two-arm study to compare oral vancomycin with an FMT-FURM as treatments for the first Clostridium difficile infection (CDI) episode among hospitalized patients. From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Specimens are cultured to isolate C. difficile, and C. difficile are assessed for the presence of genes encoding enterotoxin (tcdB), cytotoxin (tcdA), the binary toxin A (cdtA), binary toxin B (cdtB), and deletions within the negative regulator of toxin A and B production (tcdC) by polymerase chain reaction (PCR). The minimum inhibitory concentrations (MICs) of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, vancomycin, metronidazole, linezolid, fidaxomicin, and tetracycline against C. difficile are measured using the agar dilution method. Fecal samples and FMT-FURM are analyzed by 16 subunit ribosomal ribonucleic acid (16S rRNA) metagenomic sequencing.

Official Title
-----------------
Fecal Microbiota Transplant Versus Vancomycin for Treatment of Initial Clostridium Difficile Infection

Conditions
-----------------
Clostridium Difficile Infection

Intervention / Treatment
-----------------
* Other: FMT
* Drug: Vancomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of CDI (first episode) Older than 18 years old Exclusion Criteria: Patients younger than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vancomycin<br>Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days | Drug: Vancomycin<br>* Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)<br>* Other names: Glycopeptide;|
| Experimental: FMT-FURM<br>Patients in this arm receive FMT-FURM | Other: FMT<br>* Patients in the FMT group received FMT-FURM<br>* Other names: fecal microbiota transplant;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in number of evacuations | The cure of CDI was measured | up to a 2 days |
Study of Anti-telomerase T CD4 Immunity in Melanoma

Study Overview
=================
Brief Summary
-----------------
The impressive clinical responses obtained with immune checkpoint inhibitors (anti-PD-1/PDL-1, anti-CTLA-4) indicate that the presence of preexisting antitumor immune response might be required for their efficacy and highlight the critical role of antitumor T cell immunity. Recent progresses on the field of tumor immunology underline the critical role of CD4 helper 1 T lymphocyte (TH1) in the control of innate and adaptive anticancer immunity. Therefore, monitoring tumor specific TH1 response could be relevant in cancer patients. In order to monitor tumor-specific CD4 Th1 responses in most cancer patients, the investigators team have previously described novel promiscuous peptides (referred as UCP: Universal Cancer Peptides) derived from human telomerase (TERT), a prototype of shared tumor antigen. By using UCP-based immuno-assay, UCP specific Th1 immune responses will be evaluated in this study in melanoma before and after treatment.

Official Title
-----------------
Study of Anti-telomerase T CD4 Immunity in Melanoma: Predictive Biomarker and Implications for Immunotherapy

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Other: biological samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with melanoma, any stade, without history of anti-cancer treatment (surgery, chemotherapy, targeted therapy, immunotherapy...) except for patients with stade IV melanoma for which immunotherapy or targeted therapy is considered. In this case, a first-line chemotherapy treatment is allowed written informed consent Exclusion Criteria: patient with immunosuppressive treatment active autoimmune diseases, HIV, hepatitis C or B virus patients under guardianship, curatorship or under the protection of justice, pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biological samples<br>Blood samples will be collected : at baseline, 6 months after the first-line therapy or at disease progression (if occurs first). In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected : at baseline 3 months after the initiation of immunotherapy or targeted therapy at disease progression Tumor tissues will be collected if available. | Other: biological samples<br>* blood and tissue samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of spontaneous UCP-specific Th1 responses measured by ELISPOT assay |  | 12 months |
Identification of Inpatients at Risk for Poor Glycemic Control

Study Overview
=================
Brief Summary
-----------------
Both hypoglycemia and hyperglycemia can be detrimental to hospitalized patients. However, it is not clear which patients are more likely to develop significant problems with hypoglycemia or severe hyperglycemia in the hospital. Our hypothesis is that we will be able to identify risk factors present at admission that identify patients at greater risk of poor inpatient glycemic control

Official Title
-----------------
Identification of Inpatients at Risk for Poor Glycemic Control

Conditions
-----------------
Hypoglycemia, Hyperglycemia

Intervention / Treatment
-----------------
* Other: No interventions will be used in this study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years hospitalized in VUH Exclusion Criteria: -length of stay < 24 hours pregnant women patients receiving palliative/hospice care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hospitalized patients<br>patients hospitalized at VUH between 4/1/2008 to 10/31/2009 | Other: No interventions will be used in this study<br>* No interventions will be used in this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hypoglycemia or hypoglycemia |  | during hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypoglycemia among inpatients, hyperglycemia among inpatients
Self-management of Anticoagulation Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to compare self-management of anticoagulant treatment with conventional anticoagulant treatment in Norway.

Detailed Description
-----------------
Patients (n=23) on anticoagulant treatment with warfarin participated in a 27 weeks training program where they learned how to analyse International Normalised Ratio (INR) using the point-of-care instrument CoaguChek® XS and dose warfarin. The patients had to display their skills through a test before considered self-managing. They continued to measure INR weekly for 28 weeks. All INR values during the training program and self-control period were collected. In addition, the patients were told to notify if they had any complications during this period. Ten INR values and complications before enrolment was collected from INR cards and/or their general practioner. The participant filled in a quality of life-questioner at enrolment and after 28 weeks of self-management.

Official Title
-----------------
Comparison Between Conventional Anticoagulation Treatment and Self-management of Anticoagulation Treatment

Conditions
-----------------
Long-term Oral Anticoagulant Therapy

Intervention / Treatment
-----------------
* Other: Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: on life-long oral anticoagulation therapy Live in Bergen municipality Judged to be qualified for patient self-management anticoagulation treatment by their GP Motivated to follow the training program Exclusion Criteria: Drug abuse Liver disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Self-management anticoagulation treatment<br>Trained to monitor INR and dose warfarin | Other: Training<br>* Patients were trained to monitor INR and dose warfarin<br>|
| No Intervention: Conventional anticoagulation treatment<br>Before enrolment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Time in therapeutic range (TTR) |  | From 39 weeks before enrolment until 28 weeks of self management | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in number of complications |  | From 39 weeks before enrolment until 28 weeks of self management | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Warfarin, Self Care, Conventional care
A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

Study Overview
=================
Brief Summary
-----------------
This study is to assess the plasma concentration-time profile of voriconazole in adults receiving 7-day intravenous treatment and 6.5-day oral treatment. This study is also to assess the safety profile of voriconazole during the treatment period.

Official Title
-----------------
An Open-Label, Intravenous (6/4 Mg/Kg Q12h) To Oral Switch (200 Mg Q12h), Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Healthy Male And Female Adults

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: voriconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female subjects from 18 and 55 years old. Body weight between 40 kg (88 lbs) and 100 kg (220 lbs). Exclusion Criteria: Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, ocular, neurologic, or allergic disease. Subjects with any condition possibly affecting drug absorption, eg, gastrectomy. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: voriconazole<br> | Drug: voriconazole<br>* 6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.<br>* Other names: Vfend;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The pharmacokinetics of voriconazole following an intravenous to oral switch regimen in healthy adults |  | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The safety and tolerability of voriconazole following an intravenous to oral switch regimen in healthy adults |  | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacokinetics and safety of voriconazole intravenous oral adults